Related Experiment Video

Updated: Aug 12, 2026

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
04:09

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

The decision to treat: profiling benefit

C T Dollery

    Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension
    |November 1, 1985
    PubMed

    Insights

    Treating hypertension requires personalized drug selection, moving beyond general risk factors. Individual patient characteristics significantly influence treatment benefits and potential adverse effects for better outcomes.

    Area of Science:

    • Cardiology
    • Pharmacology
    • Internal Medicine

    Background:

    • Hypertension treatment decisions traditionally rely on blood pressure levels and epidemiological risk factors.
    • An underlying assumption is uniform patient response to antihypertensive medications.

    Purpose of the Study:

    • To challenge the traditional risk factor-based approach in hypertension management.
    • To advocate for individualized treatment strategies based on potential patient benefits.

    Main Methods:

    • Review of recent evidence on factors influencing drug efficacy and safety.
    • Analysis of how patient-specific variables impact treatment outcomes.

    Main Results:

    • Patient benefits from antihypertensive drugs are modulated by age, sex, race, and smoking status.
    • Pre-existing conditions like asthma, diabetes, and gout can be exacerbated by common medications.
    • Risk factor analysis alone is insufficient for optimal treatment decisions.

    Conclusions:

    • Individualized assessment of potential benefits and risks is superior to traditional risk factor analysis for hypertension treatment.
    • Personalized medicine approaches are crucial for optimizing therapeutic outcomes in hypertensive patients.

    More Related Videos

    Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index06:55

    Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index

    Published on: January 8, 2020

    Digital Spatial Profiling for Characterization of the Microenvironment in Adult-Type Diffusely Infiltrating Glioma09:17

    Digital Spatial Profiling for Characterization of the Microenvironment in Adult-Type Diffusely Infiltrating Glioma

    Published on: September 13, 2022

    Related Concept Videos

    Blind Procedures02:07

    Blind Procedures

    Ideally, the people who observe and record the children’s behavior are unaware of who was assigned to the experimental or control group, in order to control for experimenter bias. Experimenter bias refers to the possibility that a researcher’s expectations might skew the results of the study. Remember, conducting an experiment requires a lot of planning, and the people involved in the research project have a vested interest in supporting their hypotheses. If the observers knew which child was...
    Combination Therapies and Personalized Medicine02:50

    Combination Therapies and Personalized Medicine

    Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
    The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

    Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
    Pharmacogenomics: Identification of New Drug Targets01:29

    Pharmacogenomics: Identification of New Drug Targets

    Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...